Prana continues Alzheimer's drug trial in Australia

07/4/2013 | RTT News · Bloomberg Businessweek

An Australian hospital has cleared Prana Biotechnology's request to conduct a 12-month extension study of PBT2, the company's Alzheimer's disease drug candidate. PET imaging will be used to examine changes in the brains of Alzheimer's patients who have received PBT2 treatment for 12 months as part of the company's IMAGINE trial.

View Full Article in:

RTT News · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC